Zusammenfassung
Mitte der siebziger Jahre des vergangenen Jahrhunderts wurde in den Zellkernen der Leberzellen von Patienten mit chronischer Hepatitis B ein bis dahin unbekanntes Antigen, das Delta-Antigen entdeckt. Dieses gehörte zu einem zuvor unbekannten Virus, dem Hepatitis-Delta-Virus (HDV). Im Serum dieser Patienten konnte der entsprechende Antikörper nachgewiesen werden (Rizzetto et al. 1977).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Calle Serrano B, Grosshennig A, Homs M, Heidrich B, Erhardt A, Deterding K et al (2014) Development and evaluation of a baseline-event-anticipation score for hepatitis delta. J Viral Hepat 21:e154, PubMed PMID: 24673975
Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W et al (2011) Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection – The German Guideline. Z Gastroenterol 49(7):871–930, PubMed PMID: 21748700 [Epub 2011/07/13]. Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Ger
Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G et al (2000) Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 46 (3):420–426, PubMed PMID: 10673308. Epub 2000/02/15. eng
Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B et al (2014) Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60(1):87–97, PubMed PMID: 24585488
Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F et al (1977) Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 18(12):997–1003, PubMed PMID: 75123. Pubmed Central PMCID: 1411847
Virushepatitis B und D: Situationsbericht Deutschland (2013) Robert Koch Institut, 28.07.2014. Report No.
Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7(1):31–40, PubMed PMID: 20051970
Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H et al (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364(4):322–331, PubMed PMID: 21268724 [Epub 2011/01/28]. eng
Wedemeyer H, Yurdaydin C, Ernst S, Caruntu FA, Curescu MG, Yalcin K et al (2014) Prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2a plus tenofovir or placebo does not prevent hdvrna relapse after treatment: the HIDIT-2 study. The International Liver Congress, April 2014, London, S 2–3
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wursthorn, K. (2016). Hepatitis D. In: Manns, M., Schneidewind, S. (eds) Praxis der Hepatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41620-0_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-41620-0_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-41619-4
Online ISBN: 978-3-642-41620-0
eBook Packages: Medicine (German Language)